Model for end‐stage liver disease (MELD) exception for portopulmonary hypertension
Michael J. Krowka, Michael B. Fallon, David C. Mulligan, Robert G. Gish – 22 November 2006
Michael J. Krowka, Michael B. Fallon, David C. Mulligan, Robert G. Gish – 22 November 2006
Elizabeth Pomfret, Robert G. Gish, David Brandhagen – 22 November 2006
Jeffrey Punch, Robert G. Gish – 22 November 2006
Patricia Sheiner, Jacques Belghiti, Robert G. Gish, Charles Miller – 22 November 2006
Gregory J. Gores, Robert G. Gish, Debra Sudan, Charles B. Rosen – 22 November 2006
Simon Horslen, Stuart Sweet, Robert G. Gish, Ross Shepherd – 22 November 2006
John Ham, Robert G. Gish, Kevin Mullen – 22 November 2006
Sue McDiarmid, Robert G. Gish, Simon Horslen, George V. Mazariegos – 22 November 2006
Simon Horslen, Robert G. Gish, Ruth McDonald – 22 November 2006
Jocelyn Trottier, Mélanie Verreault, Susan Grepper, Didier Monté, Julie Bélanger, Jenny Kaeding, Patrick Caron, Ted T. Inaba, Olivier Barbier – 20 October 2006 – Chenodeoxycholic acid (CDCA) is a liver‐formed detergent and plays an important role in the control of cholesterol homeostasis. During cholestasis, toxic bile acids (BA) accumulate in hepatocytes causing damage and consequent impairment of their function. Glucuronidation, a conjugation reaction catalyzed by UDP‐glucuronosyltransferase (UGT) enzymes, is considered an important metabolic pathway for hepatic BA.